Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "MIT"

5631 News Found

Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial
Clinical Trials | February 04, 2026

Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial

The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated


Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
R&D | February 04, 2026

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project


SPARC announces receipt of priority review voucher associated with Sezaby approval
News | February 04, 2026

SPARC announces receipt of priority review voucher associated with Sezaby approval

A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases


Wanbury achieves first sales invoicing and commercial shipment milestone
News | February 04, 2026

Wanbury achieves first sales invoicing and commercial shipment milestone

This achievement validates global demand and catapults Wanbury into high-growth acceleration


Zydus Wellness net sales up by 113.7% in Q3 FY26
News | February 04, 2026

Zydus Wellness net sales up by 113.7% in Q3 FY26

Glucon-D maintained its leadership position with a 59% MAT market share


NATCO receives FDA's tentative approval for Erdafitinib tablets
News | February 04, 2026

NATCO receives FDA's tentative approval for Erdafitinib tablets

NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration


Lupin & TB Alliance team up to push groundbreaking TB drug forward
News | February 03, 2026

Lupin & TB Alliance team up to push groundbreaking TB drug forward

TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide


Dr. David Berman to Join Moderna as Chief Development Officer
People | February 02, 2026

Dr. David Berman to Join Moderna as Chief Development Officer

Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics


Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
News | February 02, 2026

Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY

Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%